Navigation Links
Human Genome Sciences Announces Positive Final Results Of Phase 2b,Trial of Albuferon

ved 180 mcg of subcutaneously administered peginterferon alfa-2a (Pegasys) once a week. All patients received weight-based oral ribavirin daily. The study was conducted in Australia, Canada, Czech Republic, France, Germany, Israel, Poland and Romania.

About Albuferon

Albuferon is a novel long-acting form of interferon alpha created by HGS using its proprietary albumin fusion technology. Albuferon results from the genetic fusion of human albumin and interferon alpha. Human albumin is the most prevalent naturally occurring blood protein in the human circulatory system, persisting in circulation in the body for over twenty days. Research has shown that genetic fusion of therapeutic proteins to human albumin decreases clearance and prolongs the half-life of the proteins. Recombinant interferon alpha is approved for the treatment of hepatitis C, hepatitis B and a broad range of cancers.

Albuferon is being developed by HGS and Novartis under an exclusive worldwide development and commercialization agreement entered into in June 2006. Under the agreement, HGS and Novartis will co-commercialize Albuferon in the United States, and will share clinical development costs, U.S. commercialization costs and U.S. profits equally. Novartis will be responsible for commercialization in the rest of the world and will pay HGS a royalty on those sales. Clinical development, commercial milestone and other payments to HGS could total as much as $507.5 million, including $92.5 million received to date.

About Hepatitis C

Hepatitis C is an inflammation of the liver caused by the hepatitis C virus. It is estimated that as many as 170 million people worldwide are infected with hepatitis C virus. This includes nearly four million people in the United States. When detectable levels of the hepatitis C virus in the blood persist for at least six months, a person is diagnosed as having chronic hepatitis C. The hepatitis C virus can cause serious liver disease in a
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Testing for Human Papillomavirus
2. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
3. Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog Liraglutide, Brings Patients to A1c Target
4. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
5. Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin
6. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
7. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
8. Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus
9. NCI Researchers Discover Genes That Are Turned on at High Levels in Tumor-associated Blood Vessels of Mice and Humans
10. Research Indicates Gerons Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System
11. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
Post Your Comments:
(Date:1/15/2014)... Jan. 15, 2014 /PRNewswire-iReach/ -- ChinaMarketResearchReports.com adds "China Orthopedic ... . (Photo: http://photos.prnewswire.com/prnh/20140115/MN46792 ) ... policy support, China,s orthopedic instrument ... total market size rising from 3.28 billion yuan in ...
(Date:1/15/2014)... 15, 2014  Novation, the leading health care supply chain ... value-added reseller (VAR) national contracts that expand its portfolio ... at lower costs. These include manufacturer product and service ... assistance and ongoing IT consulting support. ...
(Date:1/15/2014)... YORK , January 15, 2014 ... Ltd., the exclusive worldwide distributor of highly sophisticated agro-breeding ... on January 7, 2014, the Company,s board of directors ... Weiner as its new member of the board. ...
Breaking Medicine Technology:Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
... Conn., Sept. 16 MedClean Technologies (OTC Bulletin Board: ... technology for the treatment and disposal of medical waste ... today announced it has signed a distribution agreement with ... organization with over 125 years of combined experience in ...
... Quarterly Dividend -- ABBOTT PARK, Ill., Sept. 16 ... ... ... // Results are keyed by longUrl, so we need to grab the first one. for (var r ...
Cached Medicine Technology:MedClean Technologies Signs Distribution Agreement with Trojan Energy Systems 2MedClean Technologies Signs Distribution Agreement with Trojan Energy Systems 3Abbott Declares 347th Consecutive Quarterly Dividend 2Abbott Declares 347th Consecutive Quarterly Dividend 3Abbott Declares 347th Consecutive Quarterly Dividend 4Abbott Declares 347th Consecutive Quarterly Dividend 5Abbott Declares 347th Consecutive Quarterly Dividend 6
(Date:4/24/2014)... the corresponding terminology, and the relevance of palliation ... publications on randomized controlled trials (RCTs). This is ... Institute for Quality and Efficiency in Health Care ... report. , Together with external experts, IQWiG analysed ... lung cancer, malignant melanoma, and pancreatic cancer. For ...
(Date:4/24/2014)... 4/24/14) Dartmouth has been awarded one of 30 ... as a Lead Academic Participating Site in its new ... recipients are a select groups of investigators charged with ... cooperative groups., The NCTN grant system reflects recommendations from ... streamlines operations to achieve four goals:, Faster ...
(Date:4/23/2014)... A pilot study by Massachusetts General Hospital (MGH) investigators ... unusual treatment for a serious medical problem use ... diarrhea caused by the Clostridium difficile ( ... published online in the journal Clinical Infectious Diseases ... fecal material from donors unrelated to patients was as ...
(Date:4/23/2014)... O,Shea, M.D., scientific director at the National Institute of ... named the 2014 recipient of the Ross Prize in ... journal Molecular Medicine . The award will be ... of Sciences in Manhattan, followed by scientific presentations by ... of the National Institutes of Health. , The award, ...
(Date:4/23/2014)... an important enzyme pathway that helps prevent new cells ... condition that has been directly linked to cancer and ... found that near the end of cell division, the ... breaks in DNA are fully repaired before the parent ... This process helps safeguard against some of the most ...
Breaking Medicine News(10 mins):Health News:Palliation is rarely a topic in studies on advanced cancer 2Health News:Palliation is rarely a topic in studies on advanced cancer 3Health News:Dartmouth awarded lead role in NCI clinical trials network 2Health News:Dartmouth awarded lead role in NCI clinical trials network 3Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 2Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 3Health News:NIH scientist to receive Ross Prize in Molecular Medicine 2Health News:Study identifies enzymes that help fix cancer-causing DNA defects 2
... of terminally ill cancer patients, researchers at Dana-Farber Cancer ... cope with their illness are more likely to receive ... that often entails a lower quality of life in ... more religious patients often prefer aggressive end-of-life (EOL) treatment. ...
... economic crisis contributing to greater workplace stress, providing effective ... than ever. , Unfortunately, the approach most companies take ... unlikely to produce the best outcomes for either their ... Florida State University College of Medicine researcher. , Kathryn ...
... March 17 A federal jury in Miami today ... with a $5.3 million Medicare fraud scheme, Acting Assistant ... and U.S. Attorney R. Alexander Acosta of the Southern ... court in Miami, a jury found David Rothman, M.D., ...
... following event was announced today by the American Red ... Los Angeles Red Cross is hosting a lunch reception ... (EOC), which is ready to be activated during major ... the size of Hurricane Katrina. A video with earthquake ...
... , ... Denver -- As part of its ongoing commitment to encourage ... (AWWA), the authoritative resource on safe water, today announced it will partner ... in Las Vegas., , , , ,Debuted last year by the Southern ...
... but figures decline, report finds , , TUESDAY, March 17 ... abuse in the United States have risen dramatically over ... abuse admissions in 1997 to 5 percent in 2007, ... Alcohol was still the leading cause (40 percent) of ...
Cached Medicine News:Health News:Link between religious coping and aggressive treatment in terminally ill cancer patients 2Health News:Link between religious coping and aggressive treatment in terminally ill cancer patients 3Health News:Researcher wins $2.6 million grant for depression care study 2Health News:Researcher wins $2.6 million grant for depression care study 3Health News:Jury Convicts Two Doctors and Two Medical Assistants in $5.3 Million Medicare Fraud Scam 2Health News:Jury Convicts Two Doctors and Two Medical Assistants in $5.3 Million Medicare Fraud Scam 3Health News:Jury Convicts Two Doctors and Two Medical Assistants in $5.3 Million Medicare Fraud Scam 4Health News:State-of-the-Art Preparedness: L.A. Red Cross Opens Advanced Emergency Operations Center 2Health News:AWWA partners with WaterSmart Innovations conference 2Health News:Admissions for Prescription Painkiller Abuse on Rise 2
Angled for temporal approach. Wire 14 mm rounded blades for patient comfort. Dull finish....
Angled for temporal approach. Open 14 mm rounded blades for patient comfort. Dull finish....
Angled upward 45 degrees for temporal approach. Open 14 mm blades....
Fenestrated 14 mm blades. Self-locking mechanism. Dull finish....
Medicine Products: